Biotech ETF Rallies on Alzheimer Treatment Report
October 28, 2019 at 08:00 AM EDT
Shares of Biogen Inc. rocketed higher on Tuesday, headed for their strongest performance in 20 years, after the biotechnology company surprised investors by stating that its Alzheimer’s treatment was prepared to start the regulatory approval process, as well as from third-quarter earnings that handily beat expectations.